These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 20921236)
21. Assessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS): study protocol for a randomised controlled trial. Rice CM; Marks DI; Ben-Shlomo Y; Evangelou N; Morgan PS; Metcalfe C; Walsh P; Kane NM; Guttridge MG; Miflin G; Blackmore S; Sarkar P; Redondo J; Owen D; Cottrell DA; Wilkins A; Scolding NJ Trials; 2015 Oct; 16():463. PubMed ID: 26467901 [TBL] [Abstract][Full Text] [Related]
22. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience. Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652 [TBL] [Abstract][Full Text] [Related]
23. Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Schetelig J; Fetscher S; Reichle A; Berdel WE; Beguin Y; Brunet S; Caballero D; Majolino I; Hagberg H; Johnsen HE; Kimby E; Montserrat E; Stewart D; Copplestone A; Rösler W; Pavel J; Kingreen D; Siegert W Haematologica; 2003 Nov; 88(11):1272-8. PubMed ID: 14607756 [TBL] [Abstract][Full Text] [Related]
24. Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. Burt RK; Oliveira MC; Shah SJ; Moraes DA; Simoes B; Gheorghiade M; Schroeder J; Ruderman E; Farge D; Chai ZJ; Marjanovic Z; Jain S; Morgan A; Milanetti F; Han X; Jovanovic B; Helenowski IB; Voltarelli J Lancet; 2013 Mar; 381(9872):1116-24. PubMed ID: 23363664 [TBL] [Abstract][Full Text] [Related]
25. Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma. Georges GE; Maris MB; Maloney DG; Sandmaier BM; Sorror ML; Shizuru JA; Lange T; Agura ED; Bruno B; McSweeney PA; Pulsipher MA; Chauncey TR; Mielcarek M; Storer BE; Storb R Biol Blood Marrow Transplant; 2007 Apr; 13(4):423-32. PubMed ID: 17287157 [TBL] [Abstract][Full Text] [Related]
26. Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT. Savani BN; Labopin M; Blaise D; Niederwieser D; Ciceri F; Ganser A; Arnold R; Afanasyev B; Vigouroux S; Milpied N; Hallek M; Cornelissen JJ; Schwerdtfeger R; Polge E; Baron F; Esteve J; Gorin NC; Schmid C; Giebel S; Mohty M; Nagler A Haematologica; 2016 Feb; 101(2):256-62. PubMed ID: 26565001 [TBL] [Abstract][Full Text] [Related]
27. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation. Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846 [TBL] [Abstract][Full Text] [Related]